Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer - Top-Institutions - MDSpire

Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer

  • By

  • Lin Lin

  • Bing Han

  • July 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    our hospital
    our hospital

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #2

    German Breast Group
    German Breast Group

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #3

    University of Milan
    University of Milan

    Milan, Lombardy

    Key Differentiators

    • Oncology

  • #4

    European Institute of Oncology
    European Institute of Oncology

    Milan, Lombardy

    Key Differentiators

    • Oncology

Original Source(s)

Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer

  • by Lin Lin, Bing Han

  • July 8, 2026

Related Content

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

  • July 1, 2026

  • 1 min
Ferroptosis in chemotherapy resistance and resensitization in breast cancer: a systematic review of preclinical evidence and translational implications

Potential profile analysis of return-to-work readiness and self-efficacy in postoperative breast cancer patients who have returned to work